Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Acquired by Harvey Capital Management Inc.

Harvey Capital Management Inc. increased its stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 86.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 499,570 shares of the company's stock after acquiring an additional 232,180 shares during the period. Harvey Capital Management Inc. owned about 0.51% of Aquestive Therapeutics worth $1,449,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Deutsche Bank AG grew its position in shares of Aquestive Therapeutics by 63.9% in the fourth quarter. Deutsche Bank AG now owns 61,989 shares of the company's stock valued at $221,000 after purchasing an additional 24,170 shares during the period. Raymond James Financial Inc. acquired a new stake in Aquestive Therapeutics in the 4th quarter worth about $498,000. Two Sigma Investments LP boosted its holdings in Aquestive Therapeutics by 31.5% in the 4th quarter. Two Sigma Investments LP now owns 175,952 shares of the company's stock worth $626,000 after buying an additional 42,160 shares during the last quarter. ProShare Advisors LLC increased its stake in Aquestive Therapeutics by 79.8% during the 4th quarter. ProShare Advisors LLC now owns 25,232 shares of the company's stock worth $90,000 after buying an additional 11,200 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in Aquestive Therapeutics by 1.9% during the fourth quarter. Vanguard Group Inc. now owns 4,346,754 shares of the company's stock worth $15,474,000 after buying an additional 82,958 shares in the last quarter. 32.45% of the stock is owned by institutional investors and hedge funds.

Aquestive Therapeutics Stock Up 9.0%

NASDAQ:AQST traded up $0.33 on Wednesday, reaching $4.01. The company's stock had a trading volume of 1,505,584 shares, compared to its average volume of 1,496,124. Aquestive Therapeutics, Inc. has a 12-month low of $2.12 and a 12-month high of $5.80. The firm has a market cap of $398.31 million, a price-to-earnings ratio of -6.80 and a beta of 1.97. The stock has a 50 day moving average price of $3.04 and a 200 day moving average price of $3.00.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.07). The business had revenue of $8.72 million during the quarter, compared to the consensus estimate of $12.23 million. Equities research analysts expect that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on AQST shares. Oppenheimer started coverage on Aquestive Therapeutics in a research report on Monday, June 2nd. They set an "outperform" rating and a $7.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Tuesday, June 17th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and a consensus target price of $10.14.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.